3 Big New Catalysts for Psychedelics Stocks in 2024
- Psychedelics stocks could be buoyed by a few positive events soon. The government is now funding the study of certain psychedelics.
- 01/08/2024
|
atai Life Sciences expands its pipeline with $50M investment in Beckley Psytech
- Psychedelic drug development firm atai Life Sciences (NASDAQ:ATAI) is investing $50 million in UK-based Beckley Psytech as part of a collaboration that gives the company exposure to a Phase 2 psychedelic drug candidate. The investment will give the Berlin-headquartered company a 35.5% stake.
- 01/05/2024
|
Atai Life Sciences reports positive data from early-stage R-MDMA study
- atai Life Sciences (NASDAQ:ATAI) shares moved more than 13% higher Tuesday after the company reported positive findings from its early-stage study of EMP-01, Atai's R-isomer of MDMA. The company said that EMP-01 was well-tolerated and treatment-related adverse events were expected and largely dose-related in healthy volunteers.
- 01/02/2024
|
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
- Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include DouYu International (DOYU), Regis (RGS), 2seventy bio Inc. (TSVT), atai Life Sciences (ATAI) and GameStop (GME).
- 12/28/2023
|
5 Biotech stocks tapping into unmet mental health treatment needs
- Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are giving patients new hope for recovery and the ability to thrive.
- 12/20/2023
|
atai Life Sciences N.V. (ATAI) Upgraded to Buy: Here's Why
- atai Life Sciences N.V. (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 11/17/2023
|
Psychedelics CEOs heartened by MDMA for PTSD study results as stocks maintain momentum
- The success of a Phase 3 trial of MDMA for post-traumatic stress disorder (PTSD) which has put the therapy on track for U.S. Food and Drug Administration (FDA) approval in 2024 has been celebrated by the broader psychedelic sector.
- 09/15/2023
|
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
- NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Cantor Fitzgerald Global Healthcare Conference.
- 09/14/2023
|
atai Life Sciences to Participate in Upcoming September Investor Conferences
- NEW YORK and BERLIN, Sept. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming September Investor Conferences.
- 09/06/2023
|
atai Life Sciences N.V. (ATAI) Loses -15.43% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- atai Life Sciences N.V. (ATAI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
- 09/06/2023
|
Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies
- Atai Life Sciences is advancing RL-007 for the treatment of cognitive impairment associated with schizophrenia, with top-line results expected in the 2nd half of 2024. The company is also working on advancing COMP360 for treatment-resistant depression, with results expected in Summer 2024. Atai Life Sciences has a strong financial position with $227.5 million in cash and funding to support its operations into the 1st half of 2026.
- 09/01/2023
|
Down -24.4% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI)
- atai Life Sciences N.V. (ATAI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
- 08/21/2023
|
Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.
- Alex Carchidi returns to update investors on the psychedelics industry. Collapse, consolidation, and why you shouldn't bet on just 1 stock.
- 07/16/2023
|
COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down
- COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down
- 07/14/2023
|
FDA issues guidance on psychedelic drug clinical trials
- The U.S. Food and Drug Administration on Friday issued its first draft guidance on psychedelic drug clinical trials, outlining considerations for companies investigating the drugs' potential to treat psychiatric and substance-use disorders and other medical conditions. Psychedelics are increasingly drawing attention from researchers, biotech companies and investors interested in their potential to help address the U.S. mental-health crisis.
- 06/23/2023
|
TOMS Shoes founder is pledging $100 million for psychedelic research – Here's why he's doing it.
- Blake Mycoskie, founder of the canvas-footwear phenomenon TOMS Shoes, has committed to giving $100 million to support psychedelic research and access, Mycoskie told MarketWatch in an exclusive interview. The money will help fund academic institutions investigating psychedelics' potential to treat anxiety, depression, post-traumatic stress disorder and other mental-health issues, as well as nonprofits helping to connect patients in need with psychedelic treatments.
- 06/21/2023
|
3 Penny Stocks to Make You the Millionaire Next Door
- When it comes to investing, penny stocks often evoke a sense of intrigue and opportunity. These low-priced securities, typically traded under $5 per share, can potentially deliver substantial gains quickly.
- 05/25/2023
|
atai Life Sciences to Participate in Upcoming May Investor Conference
- NEW YORK and BERLIN, May 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Aegis Virtual Conference.
- 05/02/2023
|
After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?
- Atai's stock probably isn't going to spike by as much as Wall Street says. It has enough money for the next few years, and it could still raise even more.
- 04/20/2023
|
Why Shares of Atai Life Sciences Rose Friday
- Atai focuses on psychedelics to treat mental illnesses. The clinical-stage biopharmaceutical company said it has enough cash to last into 2026.
- 03/31/2023
|
Why Atai Life Sciences Stock Stormed Higher This Week
- In its 2022 Q4 report, Atai reiterated that it is well capitalized, with a cash runway into the first half of 2026. Its sound financial position and deep clinical pipeline appear to have sparked a wave of bargain buying this week.
- 03/31/2023
|
Atai Layoffs 2023: What to Know About the Latest ATAI Job Cuts
- The psychedelic drug boom may be taking off, but one company in the space is trimming its workforce. Atai Life Sciences (NASDAQ: ATAI ) just announced it has laid off roughly 30% of its staff.
- 03/06/2023
|
The 7 Most Promising Psychedelic Stocks to Buy in February
- Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.
- 02/05/2023
|
Down -34.59% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI)
- atai Life Sciences N.V. (ATAI) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
- 01/31/2023
|
atai Life Sciences N.V. (ATAI) Upgraded to Buy: Here's What You Should Know
- atai Life Sciences N.V. (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 01/18/2023
|
Psychedelic Sunday: Competitive Strategies
- Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?
- 01/15/2023
|
Scrutinizing Psychedelic Stocks
- What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management.
- 01/08/2023
|
atai Life Sciences shares plummet as r-ketamine candidate fails to meet primary endpoint in Phase 2a trial
- atai Life Sciences (NASDAQ:ATAI) shares tumbled more than 40% in pre-market trading on Friday after the company reported disappointing results from its subsidiary Perception Neuroscience's Phase 2a clinical trial of PCN-101 (R-ketamine), a stereoisomer of ketamine, for treatment-resistant depression. The biopharmaceutical company said in a statement that while PCN-101 demonstrated signs of efficacy across all time points out to two weeks, the trial did not meet its primary endpoint of a statistically significant change from baseline in participants' Montgomery-Åsberg Depression Rating Scale (MADRS) score at 24 hours compared to placebo.
- 01/06/2023
|
Atai says its depression treatment failed in a mid-stage clinical trial
- Shares of Atai Life Sciences NV ATAI, -2.59% tumbled about 44% in premarket trading on Friday after the company said a Phase 2a clinical trial evaluating a ketamine therapy for treatment-resistant depression did not meet the primary endpoint. Atai's stock has declined 60.1% over the past year, while the S&P 500 SPX, -1.16% is down 19.0%.
- 01/06/2023
|
3 (Risky) Tricks for Finding Monster Growth Stocks
- Stocks with big upside potential often have significant risks, too.
- 12/21/2022
|
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
- Atai, Biogen, and Sage are working to develop new treatments for mental illness.
- 12/06/2022
|
3 Big Trends Shaking Up Psychedelic Stocks
- Major positive shifts are happening, but the field faces new headwinds too.
- 11/29/2022
|
Why Shares of atai Life Sciences Climbed 14.58% on Tuesday
- The company specializes in developing psychedelics as therapies.
- 11/01/2022
|
Atai Life Sciences: Decentralized Drug Discovery Platform
- ATAI is at a value inflection point, it has slimmed its drug discovery pipeline and promises proof of concept data within two years. ATAI has taken on debt to give it a cash runway through to 2025, by which time it must have generated compelling evidence for its drugs.
- 10/06/2022
|
Is Now a Good Time to Invest In Psychedelics Stocks?
- It's risky, and you'll need to wait a while for a payoff, assuming the stars align for there to be one.
- 09/27/2022
|
Buying These 2 Battered Growth Stocks Right Now Could Be Brilliant
- They haven't experienced any setbacks, but their shares are still down.
- 09/09/2022
|
2 Top Trends to Invest $2,000 in Ahead of the Crowd
- These two trends on the frontier of medicine could present lucrative opportunities for investment.
- 09/05/2022
|
7 Psychedelics Stocks to Buy for a Big Drug Boom
- Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and sensory perceptions.
- 08/30/2022
|
Atai Life Sciences N.V.'s (ATAI) CEO Florian Brand on Q2 2022 Results - Earnings Call Transcript
- Atai Life Sciences N.V. (NASDAQ:ATAI ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Greg Weaver – Chief Financial Officer Stephen Bardin – Deputy Chief Financial Officer Florian Brand – Chief Executive Officer Srini Rao – Chief Scientific Officer Conference Call Participants Judah Frommer – Credit Suisse Andrew Tsai – Jefferies LLC Greg Weaver Hi, everyone.
- 08/15/2022
|
The Growth Potential Of Psychedelics Stocks And ETFs
- On July 13, 2022, two amendments passed in the House of Representatives that would provide psychedelic drug treatment to veterans and active duty service members. A documentary based on Michael Pollan's 2018 book, "How to Change Your Mind," is one of Netflix's most-watched shows.
- 07/28/2022
|
New Regulations for Psychedelics? Here's What Investors Need to Know
- There are a couple of proposed regulations and policies in the pipeline.
- 07/22/2022
|
5 Top Stocks Cathie Wood Bought This Week
- Cathie Wood is still buying the dip and believes that deflationary forces may soon show out. Here are five top stocks she bought this week.
- 07/15/2022
|
Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer
- ATAI is backed by Peter Thiel. Its decentralized business model is pretty unique.
- 07/07/2022
|
Will Tech Stocks Recover? 3 Names To Buy
- Tech stocks have crashed, but Wall Street should eventually remember why the love affair began in the first place. After the tech crash, it makes sense to invest in a large quantity of names.
- 07/01/2022
|
Atai Life Sciences N.V.: A First Take
- Shares of mental health biopharma Atai Life Sciences N.V. have fallen some two-thirds from their June 2021 IPO pricing as the biotech market continues to crater. The company's approach of identifying (in many instances psychedelic) compounds that have been tested in previous human trials marginally de-risks its programs.
- 06/02/2022
|
Atai Life Sciences And The Future Of Psychedelics For Mental Health
- ATAI has a large portfolio of drugs, mainly psychedelics, that can be used to treat mental health conditions when other options have failed. There is ample room for new drug developments in this space, given that R&D for new drug developments has been declining.
- 05/27/2022
|
Best Penny Stocks To Buy? 3 With Unusual Options Activity Today
- Penny stocks to watch with unusual options volume today. The post Best Penny Stocks To Buy?
- 05/18/2022
|
atai Life Sciences' (ATAI) CEO Florian Brand on Q1 2022 Results - Earnings Call Transcript
- atai Life Sciences N.V. (NASDAQ:ATAI ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Greg Weaver – Chief Financial Officer Florian Brand – Chief Executive Officer Srini Rao – Chief Scientific Officer Conference Call Participants Charles Duncan – Cantor Ritu Baral – Cowen Greg Weaver Hi everyone, I'm Greg Weaver, CFO of atai Life Sciences.
- 05/16/2022
|
CORRECTION - atai Life Sciences to Announce First Quarter 2022 Financial Results and Business Update
- NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued yesterday under the headline "atai Life Sciences to Announce First-Quarter 2022 Financial Results" by atai Life Sciences N.V. (Nasdaq: ATAI), please note the first and second paragraphs, which contained statements referencing the 2022 IR financial results posting and executives on the video interview, as well as forward-looking statements, have been modified. The corrected release follows:
- 05/05/2022
|
atai Life Sciences to Announce First-Quarter 2022 Financial Results
- NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will announce its first-quarter 2022 financial results by posting them on the IR portion of its website. Please visit the atai investor relations website at https://ir.atai.life to view Q1'22 financial results and press release.
- 05/04/2022
|
Penny Stocks To Buy Now? Insiders Threw Big Money At These 4 Stocks
- Penny stocks to buy according to these insiders. The post Penny Stocks To Buy Now?
- 05/03/2022
|
10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?
- Are these Cathie Wood penny stocks a buy right now? The post 10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?
- 04/28/2022
|
atai Life Sciences to Participate in Upcoming April Investor Conference
- NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference in April:
- 04/19/2022
|
Interested in Investing in Psychedelics? Check Out This Podcast.
- And other market news.
- 04/19/2022
|
atai Life Sciences N.V. (ATAI) CEO Florian Brand on Q4 2021 Results - Earnings Call Transcript
- atai Life Sciences N.V. (ATAI) CEO Florian Brand on Q4 2021 Results - Earnings Call Transcript
- 03/30/2022
|
atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
- NEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a webcast on Wednesday, March 30, 2022 at 8:30 a.m. ET to discuss its financial results for the fourth quarter 2021 and provide a business update.
- 03/23/2022
|
atai Life Sciences to Participate in Upcoming March Investor Conferences
- NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conferences in March:
- 03/21/2022
|
5 Psychedelic Therapeutics Decisions Coming in 2022
- Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials.
- 01/25/2022
|
atai Life Sciences to Participate in Upcoming January Investor Conference
- NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference today:
- 01/10/2022
|
3 Psychedelic Stocks to Play the Shroom Boom
- Psychedelic substances are often grouped together with cannabis, but there are some important distinctions. ATAI, CMPS and FTRP are some of the best stocks in the space.
- 12/22/2021
|
ATAI Life Sciences Stock (ATAI): Why The Price Increased Over 11% Today
- The stock price of ATAI Life Sciences NV (NASDAQ: ATAI) increased by over 11% today. This is why it happened.
- 12/16/2021
|
9 Psychedelic Stocks to Watch For 2022
- The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S. As a result, the psychedelics market is projected to grow 12.4% annually, reaching $10.75 billion in 2027.
- 12/06/2021
|
Atai Life Sciences N.V. (ATAI) CEO Florian Brand on Q3 2021 Results - Earnings Call Transcript
- Atai Life Sciences N.V. (ATAI) CEO Florian Brand on Q3 2021 Results - Earnings Call Transcript
- 11/15/2021
|
Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential
- Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why.
- 11/11/2021
|
atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update
- NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, November 15, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and provide a business update.
- 11/08/2021
|
atai Life Sciences to Participate in Upcoming November Investor Conferences
- NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in the following upcoming investor conferences in November:
- 11/05/2021
|
This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop
- Psychedelics have picked up more and more momentum on Wall Street, with famed investors such as Kevin O'Leary and Peter Thiel recognizing the potential in the psych drug industry. Psychedelic drugs, such as psilocybin mushrooms and LSD, were once seen merely as a way for college students and concert goers to escape reality or at least enhance it.
- 11/02/2021
|
What Is Precision Psychiatry? Biotech Company Leverages New Approach To Mental Health Disorders
- Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelics space, announced the formation of a new subsidiary, called PsyProtix. PsyProtix is a precision psychiatry company focused on developing therapeutics for treatment-resistant depression and other mental health indications.
- 10/11/2021
|
Atai Life Launches Depression-Focused Firm
- Atai Life Sciences NV (NASDAQ: ATAI) has launched PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. PsyProtix is a precision psychiatry company focused on developing therapeutics for treatment-resistant depression (TRD) and other mental health indications.
- 10/11/2021
|
atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx's Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data
- NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has entered into an amended and restated loan agreement (“Loan Agreement”) with strategic partner IntelGenx Technologies Corp. (“IntelGenx”) to support IntelGenx's conditionally approved graduation from the TSX Venture Exchange to the Toronto Stock Exchange (“TSX”). Completion of the uplisting and the commencement of trading of IntelGenx's common shares, 8% convertible debentures with a maturity date of June 30, 2022, and share purchase warrants expiring on February 11, 2023 is subject to the satisfaction by IntelGenx of all of the final conditions of listing.
- 09/15/2021
|
Can Ketamine For Depression Be Improved? New Study Will Looks Into Ketamine Analog Arketamine
- Perception Neuroscience, an Atai Life Sciences (NASDAQ:ATAI) subsidiary, is starting a Phase 2a clinical trial on PCN-101, its lead drug candidate. The study will evaluate the safety and efficacy of a proprietary formulation of arketamine that could have a similar therapeutic action to ketamine in the treatment of depression, with less dissociative effects.
- 09/14/2021
|
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression
- NEW YORK and BERLIN, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced the initiation of a Phase 2a clinical study to evaluate the safety and efficacy of PCN-101 (R-ketamine). R-ketamine is a stereoisomer of ketamine being developed for therapeutic treatment of psychiatric disorders such as Treatment Resistant Depression (TRD). The Phase 2a clinical trial has received the necessary regulatory and ethics approvals to initiate the study.
- 09/14/2021
|
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression
- BERLIN and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its digital therapeutic platform Introspect Digital Therapeutics, Inc. (“Introspect”), today announced a usability study of Introspect's digital therapeutic (DTx) app technology in support of standard of care ketamine therapy for patients with treatment resistant depression (TRD) in collaboration with Kadima Neuropsychiatry. TRD impacts 100 million people globally, close to a third of the 300 million diagnosed with depression, many of whom are geographically restricted in their ability to access in-person psychological care.
- 09/09/2021
|
Time to Buy the Magic Stocks? Magic Mushrooms, That Is.
- The first state to legalize cannabis for medical use was California, in 1996. In 2001, medical marijuana was approved in Canada.
- 09/08/2021
|
atai Life Sciences to Participate in Upcoming September Investor Conferences
- BERLIN, Sept. 03, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in in the following upcoming investor conferences in September:
- 09/03/2021
|
Atai shares pop after earnings: Company's CEO talks about mental health and psychedelics
- Atai Life Sciences, a biopharmaceutical and psychedelic company reported its first earnings since going public in June. Florian Brand, Atai's CEO and co-founder joins Closing Bell to discuss the future of his company and bringing its product to market.
- 08/16/2021
|
Atai Life Sciences N.V. (ATAI) CEO Florian Brand on Q2 2021 Results - Earnings Call Transcript
- Atai Life Sciences N.V. (ATAI) CEO Florian Brand on Q2 2021 Results - Earnings Call Transcript
- 08/16/2021
|
3 Disruptive Mental Health Stocks to Consider Buying Before They're Huge
- They're the first pioneers in exciting new markets.
- 08/14/2021
|
atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions
- BERLIN, Aug. 12, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of Revixia Life Sciences (Revixia), a wholly owned subsidiary developing Salvinorin A (SalA) to treat a variety of mental health disorders.
- 08/12/2021
|
atai Life Sciences to Host Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Business Update
- BERLIN, Aug. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, August 16, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2021 and provide a business update.
- 08/09/2021
|
atai Life Sciences to Present at the 41st Annual Canaccord Genuity Growth Conference
- BERLIN, Aug. 06, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity Growth Conference, to be held virtually from August 10-12, 2021.
- 08/06/2021
|
Atai Launches New "Nose-To-Brain" Drug Delivery Company To Interact With Its Portfolio Of Psychedelics Subsidiaries
- Atai Life Sciences (NASDAQ:ATAI) is launching a new company that will interact with its portfolio of psychedelics and tech start-ups looking at novel mental health treatments. InnarisBio Inc., as the company has been baptized, is being launched as a collaboration between Atai and UniQuest, a company managing and commercializing intellectual property developed by The University of Queensland in Australia.
- 07/28/2021
|
atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai's platform of mental health therapeutic programs
- BERLIN and BRISBANE, Australia, July 28, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (“atai” or the “Company”) (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and UniQuest, Australia's leading university technology transfer company commercializing the research of The University of Queensland (UQ), today announced the launch of InnarisBio Inc. (InnarisBio), to develop a novel sol-gel intranasal drug delivery technology to improve treatments for mental health disorders.
- 07/28/2021
|
Investment Banks Bullish On Psychedelics Co Atai Life Sciences: Cantor, Credit Suisse, Citigroup, Cowen, Aegis And Others Launch Coverage, Positive Ratings
- This week, a number of financial firms and investment banks initiated coverage of Atai Life Sciences (NASDAQ:ATAI), the Peter Thiel-backed biotech exploring a host of psychedelic compounds and treatments for use in mental health. Ratings ranged from a very sober sector performance rating from RBC Capital Markets with a $19 12-month price target, to a very bullish Overweight rating from Cantor Fitzgerald, which gave Atai a 12-month price target of $45.
- 07/16/2021
|
Leading U.S.-Based Psychedelic Healthcare VC Fund Launches with $35 Million Raised to Tackle the Growing Global Mental Health Crisis
- CHICAGO, July 15, 2021 /PRNewswire/ -- P alo Santo , the leading U.S.-based psychedelic investment fund, announced its launch with an initial $35 million in capital raised and an active portfolio of 20 companies. The diversified venture fund is focused on tackling the growing global mental health crisis by investing in innovative psychedelic-based and adjacent therapies that are poised to shape the future of psychiatry and fields beyond.
- 07/15/2021
|
Chewy, Brinker, Cleveland-Cliffs, Nvidia and More Thursday Afternoon Analyst Calls
- With the trading day more than halfway over, the broad markets saw a loss across the board.
- 07/08/2021
|
atai Life Sciences to Present at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
- BERLIN, Germany, July 07, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that it will present and participate in one-on-one investor meetings at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on July 13, 2021.
- 07/07/2021
|
Got $1,000? Consider This Freshly IPO'd Psychedelic Biotech
- It's off to a running start.
- 07/03/2021
|
5 Stocks With High Insider Interest
- Unique insider buys at high levels through the second quarter
- 07/01/2021
|
Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public
- Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelic space, had its Nasdaq debut on Friday. The Berlin-based company is joining an exclusive group of start-ups in the psychedelics sector to IPO this year on the Nasdaq, including MindMed (NASDAQ:MNMD) and Compass Pathways (NASDAQ:CMPS).
- 06/18/2021
|
Peter Thiel-backed psychedelic start-up's shares pop in Wall Street debut
- The German biotech's initial public offering was priced Thursday night at $15 per share, the high end of the expected range.
- 06/18/2021
|
Peter Thiel's Atai Life Sciences and 5 Other Companies List Shares
- Going public on Friday: atai Life Sciences, Ambrx Biopharma, Century Therapeutics, Codex DNA, Cyteir Therapeutics, and Femasys.
- 06/18/2021
|
Thiel-backed psychedelic drugmaker valued at $3.2B in Nasdaq debut
- Shares of Atai Life Sciences, backed by billionaire investor Peter Thiel, surged 40 percent in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of $3.19 billion. The Berlin-based biotech startup, which is exploring the use of psychedelic treatments for mental illnesses, raised $225 million from selling 15 million shares in.
- 06/18/2021
|
Thiel-backed psychedelics startup Atai valued at $3.19 billion in Nasdaq debut
- (Reuters) -Shares of Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, surged 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of $3.19 billion.
- 06/18/2021
|
Atai Life Sciences founder on using psychedelics to treat mental illness
- Atai Life Sciences, a biotech company that uses psychedelics to treat mental illness, is going public on the Nasdaq Friday. Christian Angermayer, Atai Life Sciences founder, joined "Squawk Box" on Friday to discuss the company's mission and public debut.
- 06/18/2021
|
atai Life Sciences Announces Pricing of Upsized Initial Public Offering
- BERLIN, June 17, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the pricing of its upsized initial public offering in the United States of 15,000,000 common shares at a price to the public of $15.00 per share. All common shares are being offered by atai. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by atai, are expected to be $225.0 million. In addition, atai has granted the underwriters a 30-day option to purchase up to an additional 2,250,000 common shares at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on June 22, 2021, subject to customary closing conditions.
- 06/17/2021
|
